WO2006052521A3 - Medical devices and compositions for treating restenosis - Google Patents

Medical devices and compositions for treating restenosis Download PDF

Info

Publication number
WO2006052521A3
WO2006052521A3 PCT/US2005/039354 US2005039354W WO2006052521A3 WO 2006052521 A3 WO2006052521 A3 WO 2006052521A3 US 2005039354 W US2005039354 W US 2005039354W WO 2006052521 A3 WO2006052521 A3 WO 2006052521A3
Authority
WO
WIPO (PCT)
Prior art keywords
medical devices
compositions
ikbα
crm
embodiment includes
Prior art date
Application number
PCT/US2005/039354
Other languages
French (fr)
Other versions
WO2006052521A2 (en
Inventor
Adam Blakstvedt
Jesus Wilfredo Casas-Bejar
Jamie Rae Williams
Molly Schiltgen
Original Assignee
Medtronic Vascular Inc
Adam Blakstvedt
Jesus Wilfredo Casas-Bejar
Jamie Rae Williams
Molly Schiltgen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Vascular Inc, Adam Blakstvedt, Jesus Wilfredo Casas-Bejar, Jamie Rae Williams, Molly Schiltgen filed Critical Medtronic Vascular Inc
Priority to EP05818130A priority Critical patent/EP1824532A2/en
Publication of WO2006052521A2 publication Critical patent/WO2006052521A2/en
Publication of WO2006052521A3 publication Critical patent/WO2006052521A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Medical devices and related methods for making and using same suitable for treating or inhibiting restenosis are proved. Specifically, compositions and methods for I kappa B alpha (IkBα)-nuclear factor kβ (NFkβ) complex breakdown inhibition are provided. One embodiment includes a CRM-1 protein binding composition such as leptomycin B. Another embodiment includes a combination of a CRM-1 protein binding composition and a nucleic acid encoding for mammalian IkBα. Medical devices disclosed include catheters and vascular stents.
PCT/US2005/039354 2004-11-11 2005-11-01 Medical devices and compositions for treating restenosis WO2006052521A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05818130A EP1824532A2 (en) 2004-11-11 2005-11-01 Medical devices and compositions for treating restenosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/987,021 US20060099235A1 (en) 2004-11-11 2004-11-11 Medical devices and compositions useful for treating or inhibiting restenosis
US10/987,021 2004-11-11

Publications (2)

Publication Number Publication Date
WO2006052521A2 WO2006052521A2 (en) 2006-05-18
WO2006052521A3 true WO2006052521A3 (en) 2006-09-14

Family

ID=36181775

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/039354 WO2006052521A2 (en) 2004-11-11 2005-11-01 Medical devices and compositions for treating restenosis

Country Status (3)

Country Link
US (1) US20060099235A1 (en)
EP (1) EP1824532A2 (en)
WO (1) WO2006052521A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
DE60135455D1 (en) 2000-05-16 2008-10-02 Univ Minnesota IT OF MULTI-NOZZLE ARRANGEMENT
US7247338B2 (en) * 2001-05-16 2007-07-24 Regents Of The University Of Minnesota Coating medical devices
US8088404B2 (en) * 2003-03-20 2012-01-03 Medtronic Vasular, Inc. Biocompatible controlled release coatings for medical devices and related methods
US9687368B2 (en) * 2003-08-13 2017-06-27 Medtronic Vascular, Inc. Biocompatible controlled release coatings for medical devices and related methods
EP1758633B1 (en) * 2004-05-13 2015-03-18 Medtronic Vascular, Inc. Methods for compounding a therapeutic agent to the adventitia of a vessel
JP2009505727A (en) 2005-08-25 2009-02-12 メドトロニック ヴァスキュラー インコーポレイテッド Nitric oxide releasing biodegradable polymers useful as medical devices and their coatings
CN1962155A (en) * 2005-11-10 2007-05-16 鸿富锦精密工业（深圳）有限公司 CO2 laser welding apparatus
EP2529761B1 (en) * 2006-01-31 2017-06-14 Nanocopoeia, Inc. Nanoparticle coating of surfaces
US9108217B2 (en) 2006-01-31 2015-08-18 Nanocopoeia, Inc. Nanoparticle coating of surfaces
CA2637883C (en) * 2006-01-31 2015-07-07 Regents Of The University Of Minnesota Electrospray coating of objects
US8241619B2 (en) 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US9040816B2 (en) * 2006-12-08 2015-05-26 Nanocopoeia, Inc. Methods and apparatus for forming photovoltaic cells using electrospray
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8852620B2 (en) * 2007-07-20 2014-10-07 Medtronic Vascular, Inc. Medical devices comprising polymeric drug delivery systems with drug solubility gradients
US8273828B2 (en) * 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
US20090326646A1 (en) * 2008-06-27 2009-12-31 Medtronic Vascular, Inc. Methods and Apparatus for Multiple Cured Formulation Coated Stents
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
CN102933231B (en) 2010-02-10 2015-07-29 伊缪诺金公司 CD20 antibody and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054899A1 (en) * 1999-12-15 2002-05-09 Zeldis Jerome B. Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
WO2004009081A1 (en) * 2002-07-18 2004-01-29 Pedro Cuevas Sanchez Use of neomycin in the preparation of medicaments that are used in the treatment of diseases caused by hyperactivation of kinase proteins activated by mitogens (mapk) or by transcription factors
WO2004069201A2 (en) * 2003-02-03 2004-08-19 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
ES2214105A1 (en) * 2002-07-18 2004-09-01 Pedro Cuevas Sanchez Treatment of diseases mediated by mitogen activated protein kinase hyperactivation, e.g. restenosis, arteriosclerosis, glioma or especially psoriasis, using neomycin or its derivative
JP2004267368A (en) * 2003-03-06 2004-09-30 Kawasumi Lab Inc Drug release stent
US20040243218A1 (en) * 2002-10-08 2004-12-02 Schaeffer Darin G. Stent with ring architecture and axially displaced connector segments
WO2005016400A1 (en) * 2003-08-14 2005-02-24 Blue Medical Devices B.V. Endoluminal prosthesis comprising a therapeutic agent
WO2006034345A2 (en) * 2004-09-20 2006-03-30 Research Development Foundation Avicin-coated stents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063805A1 (en) * 2002-09-19 2004-04-01 Pacetti Stephen D. Coatings for implantable medical devices and methods for fabrication thereof
US8088404B2 (en) * 2003-03-20 2012-01-03 Medtronic Vasular, Inc. Biocompatible controlled release coatings for medical devices and related methods
US7446196B2 (en) * 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054899A1 (en) * 1999-12-15 2002-05-09 Zeldis Jerome B. Methods and compositions for the prevention and treatment of atherosclerosis, restenosis and related disorders
WO2004009081A1 (en) * 2002-07-18 2004-01-29 Pedro Cuevas Sanchez Use of neomycin in the preparation of medicaments that are used in the treatment of diseases caused by hyperactivation of kinase proteins activated by mitogens (mapk) or by transcription factors
ES2214105A1 (en) * 2002-07-18 2004-09-01 Pedro Cuevas Sanchez Treatment of diseases mediated by mitogen activated protein kinase hyperactivation, e.g. restenosis, arteriosclerosis, glioma or especially psoriasis, using neomycin or its derivative
US20040243218A1 (en) * 2002-10-08 2004-12-02 Schaeffer Darin G. Stent with ring architecture and axially displaced connector segments
WO2004069201A2 (en) * 2003-02-03 2004-08-19 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
JP2004267368A (en) * 2003-03-06 2004-09-30 Kawasumi Lab Inc Drug release stent
WO2005016400A1 (en) * 2003-08-14 2005-02-24 Blue Medical Devices B.V. Endoluminal prosthesis comprising a therapeutic agent
WO2006034345A2 (en) * 2004-09-20 2006-03-30 Research Development Foundation Avicin-coated stents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200419, Derwent World Patents Index; Class B03, AN 2004-203437, XP002387967, "Treatment of diseases mediated by mitogen activated protein kinase hyperactivation, e.g. restenosis, arteriosclerosis, glioma or especially psoriasis, using neomycin or its derivative." *
PATENT ABSTRACTS OF JAPAN vol. 2003, no. 12 5 December 2003 (2003-12-05) *

Also Published As

Publication number Publication date
US20060099235A1 (en) 2006-05-11
EP1824532A2 (en) 2007-08-29
WO2006052521A2 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
WO2006052521A3 (en) Medical devices and compositions for treating restenosis
SG156650A1 (en) Thienopyrimidines useful as aurora kinase inhibitors
WO2007079164A3 (en) Protein kinase inhibitors
EP1140840A4 (en) -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2006020768A3 (en) Chemically modified oligonucleotides
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
DE60328486D1 (en) COMPOSITIONS AND METHODS FOR COATING MEDICAL IMPLANTS
WO2007026251A8 (en) Use of dual c-kit/fgfr3 inhibitors for treating multiple myeloma
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2007041358A3 (en) Substituted pyrazole compounds
WO2006073457A8 (en) Bioactive compounds and methods of uses thereof
HUP0400823A3 (en) Heterocyclic compounds for treating aging-related and diabetic vascular complications, their preparation and pharmaceutical compositions containing them
GEP20146055B (en) Inhibitors of renal outer medullary potassium channel
WO2009064486A3 (en) Inhibitors of pim protein kinases, compositions, and methods for treating cancer
TW200714283A (en) Method and composition for treating peripheral vascular diseases
WO2007059007A3 (en) Markers of definitive endoderm
WO2007067781A3 (en) 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2008013589A3 (en) Treatment of ras-expressing tumors
WO2005074632A3 (en) Methods and compositions for treating cancer
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP2702988A3 (en) Novel compositions and methods for treating hyperproliferative diseases
WO2007120333A3 (en) Tetracyclic kinase inhibitors
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2003097835A3 (en) Pharmaceutical compositions for the treatment of cancer
WO2006066957A3 (en) Sulfonamido-macrocycles as tie2 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005818130

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005818130

Country of ref document: EP